# Dr. Li Jie

> Dr. Li Jie is a angel investor at Redhill Capital backing Biopharma and Health Care. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Redhill Capital](https://shizune.co/investors/profile/redhill-capital)
- Total investments: 5
- Last investment: Oct 2023
- Lead investor: 80%
- Last updated: Aug 2026

Dr. Li Jie is a angel investor at Redhill Capital focused on Biopharma and Health Care. Dr. Li Jie is Managing Director of Danlu Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 2 | 40% |
| Health Care | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| Biotechnology | 1 | 20% |
| Information Technology | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Angel | 2 | 40% |
| Seed | 1 | 20% |
| Series A | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Inflamax Pharmaceuticals | Inflamax Pharmaceuticals is a biomedical technology company that specializes in the innovation and development of immune-inflammatory drugs. |  | Angel | Oct 20, 2023 |  |
| Metanovas Biotech | Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning. | $10M | Angel | Mar 31, 2022 |  |
| Metanovas Biotech | Metanovas is a metabolic drug developer focused on combining artificial intelligence with life sciences, using deep learning. | $10M | Seed | Mar 30, 2022 |  |
| Vibrant | Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects tocontinuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization.It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China. | $15.7M | Venture - Series Unknown | Jan 13, 2022 |  |
| Xinji Pharmaceuticals | Xinji Pharmaceuticals is mainly engaged in the R&D of new drug preparations and drug release systems. The company is especially involved in the application and promotion of drug-controlled release, sustained release, and targeted drug release technologies in the industrialization of biomedicine. | $15.7M | Series A | Dec 07, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Sinopharm Capital](https://shizune.co/investors/profile/sinopharm-capital) — VC Fund, 2 deals together
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 1 deal together
- [Jinyi Capital](https://shizune.co/investors/profile/jinyi-capital-9c2c) — VC Fund, 1 deal together
- [Matrix Partners China](https://shizune.co/investors/profile/matrix-partners-china) — VC Fund, 1 deal together
- [NeuX Capital](https://shizune.co/investors/profile/neux-capital) — VC Fund, 1 deal together
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 1 deal together

## About Redhill Capital

VC Fund · Guangzhou, China

Redhill Capital is a venture capital firm specializing in early stage investment. It primary invests in medical industry.

4 contacts available at Redhill Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Frank Su | Founding Partner | https://shizune.co/investors/profile/frank-su |
| Cherry Lu | Founding and Managing Partner | https://shizune.co/investors/profile/cherry-lu |
| Dr. Li Jie | Managing Director | https://shizune.co/investors/profile/dr-li-jie |
| Lu Qinchao | Redhill Capital is a venture capital firm focusing on the medical industry. | https://shizune.co/investors/profile/lu-qinchao |

## Similar investors

### Similar stage
- [LVX Ventures](https://shizune.co/investors/profile/letsventure) — VC Fund
- [ZhenFund](https://shizune.co/investors/profile/zhenfund) — VC Fund
- [IAN Group](https://shizune.co/investors/profile/indian-angel-network) — VC Fund

## FAQ

### What does Dr. Li Jie invest in?

Dr. Li Jie invests primarily in Biopharma, Health Care and Pharmaceutical startups, most often at Angel and Seed stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dr. Li Jie last invest?

The most recent investment recorded for Dr. Li Jie closed in Oct 2023. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co